Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease.
Publication/Presentation Date
1-1-2020
Abstract
Sickle cell disease (SCD) is an inherited hemoglobinopathy that leads to significant lifetime morbidity and early mortality. An enhanced understanding of the complex pathophysiology of the disease has elucidated novel therapeutic targets for which new therapies are in development. In order to increase the therapeutic landscape, it has been important to identify the blood vessel and more specifically the endothelium as the target organ in this complex disease. Through this lens, we present a review of new anti-adhesion therapies for SCD in development. The long-term promise of multimodal therapies for SCD is finally on the horizon.
Volume
107
Issue
1
First Page
140
Last Page
146
ISSN
1532-6535
Published In/Presented At
Kanter, J., & Lanzkron, S. (2020). Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease. Clinical pharmacology and therapeutics, 107(1), 140–146. https://doi.org/10.1002/cpt.1682
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31617585
Department(s)
Administration and Leadership
Document Type
Article